Nasus Pharma to Detail Pipeline at Investor Forum
Event summary
- Nasus Pharma will present at the virtual Life Sciences Investor Forum on March 11, 2026, at 12:30 p.m. ET.
- CEO Dan Teleman will lead the presentation, with one-on-one meetings available by request.
- The forum is hosted by VirtualInvestorConferences.com and registration is available via a provided link.
- Nasus Pharma is developing NS002, an intranasal epinephrine product candidate as a needle-free alternative for anaphylaxis.
The big picture
Nasus Pharma’s focus on intranasal drug delivery addresses a growing need for rapid and convenient administration of emergency medications. The company’s PBI technology represents a potential advantage over existing liquid nasal formulations, but faces competition from established autoinjector manufacturers. Investor interest will hinge on demonstrating clinical efficacy and a viable path to commercialization within a crowded market.
What we're watching
- Clinical Progress
- The forum presentation will likely highlight progress on NS002, and the success of the trial will be critical to investor confidence given the competitive landscape of epinephrine delivery methods.
- Market Adoption
- The ease of use and needle-free nature of Nasus’ intranasal delivery system could drive adoption, but the company must demonstrate a clear value proposition and overcome potential patient and physician hesitancy.
- Financial Runway
- Given the clinical-stage nature of Nasus Pharma, the company’s ability to secure additional funding or partnerships will be essential to support ongoing development and commercialization efforts.
Related topics